Waverley Pharma Inc. WAVE.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 227.20K | 209.30K | 213.00K | 200.10K | 278.70K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 227.20K | 209.30K | 213.00K | 200.10K | 278.70K |
| Cost of Revenue | 146.20K | 141.10K | 127.80K | 150.30K | 145.80K |
| Gross Profit | 81.00K | 68.20K | 85.20K | 49.90K | 132.90K |
| SG&A Expenses | 150.90K | 157.80K | 193.70K | 177.90K | 125.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 297.90K | 298.90K | 321.80K | 336.90K | 271.30K |
| Operating Income | -70.70K | -89.60K | -108.80K | -136.70K | 7.40K |
| Income Before Tax | -103.80K | -120.60K | -141.50K | -171.60K | -20.10K |
| Income Tax Expenses | -- | -- | 0.00 | 1.20K | -- |
| Earnings from Continuing Operations | -103.80K | -120.60K | -141.50K | -172.80K | -20.10K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -103.80K | -120.60K | -141.50K | -172.80K | -20.10K |
| EBIT | -70.70K | -89.60K | -108.80K | -136.70K | 7.40K |
| EBITDA | -55.80K | -74.70K | -98.40K | -121.80K | 22.30K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 54.00M | 54.00M | 54.00M | 54.00M | 54.00M |
| Average Diluted Shares Outstanding | 54.00M | 54.00M | 54.00M | 54.00M | 54.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |